{"product_id":"9781032919522","title":"Ocular Drug Delivery Systems Barriers and Application of Nanoparticulate Systems","description":"\u003ch1\u003eOcular Drug Delivery Systems\u003c\/h1\u003e\u003ch2\u003eBarriers and Application of Nanoparticulate Systems\u003c\/h2\u003e\u003ch3\u003eDeepak Thassu | Gerald J. Chader\u003c\/h3\u003e\u003cdiv\u003e\u003cb\u003eMedical \/ Pharmacy\u003c\/b\u003e\u003c\/div\u003e\u003cbr\u003e\u003cdiv\u003e\n\u003cp\u003eDrug discovery for ocular diseases has taken great strides in the last two decades. From cornea to choroid, new drugs have been formulated to address a great variety of ocular diseases. Yet without good drug delivery systems, these drugs are less effective than they might be or could even cause serious side effects. \u003cb\u003eOcular Drug Delivery Systems: Barriers and Application of Nanoparticulate Systems\u003c\/b\u003e presents research on the development of currently marketed devices and recent trends in the topical delivery of drugs to the posterior of the eye. \u003c\/p\u003e\n\u003cp\u003eWith contributions from leading pharmaceutical researchers and industry experts, eye researchers, surgeons, pharmacologists from academia, the National Eye Institute, and leading ophthalmic companies such as Pfizer, Allergan, and Novartis, the book presents the state of the art in the use of nanoparticles in ocular drug delivery systems and also sets the stage for future developments.\u003cbr\u003e\u003cbr\u003eThis volume provides both a current evaluation and a future roadmap for developments in ocular drug delivery. The subjects range from biological needs to material challenges and finally to clinical applications for improving drug delivery for conditions where treatments already exist. It also explores areas where effective drugs may be currently available but yet need a safe, efficient, and efficacious delivery vehicle.\u003c\/p\u003e\n\u003c\/div\u003e\u003cdiv\u003e\n\u003cp\u003e\u003cstrong\u003eDeepak Thassu\u003c\/strong\u003e is the Vice President of Pharmaceutical Development at Pharmanova, Inc., in Victor, New York.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eGerald Chader\u003c\/strong\u003e is Chief Scientific Officer of the Doheny Retina Institute at USC Medical School in Los Angeles.\u003c\/p\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublication Date: \u003c\/td\u003e\n\u003ctd\u003e14 October 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublisher: \u003c\/td\u003e\n\u003ctd\u003eCRC Press\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImprint: \u003c\/td\u003e\n\u003ctd\u003eCRC Press\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eISBN-13: \u003c\/td\u003e\n\u003ctd\u003e9781032919522\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat: \u003c\/td\u003e\n\u003ctd\u003ePaperback softback\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePage Count: \u003c\/td\u003e\n\u003ctd\u003e474\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeight (oz): \u003c\/td\u003e\n\u003ctd\u003e28.25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e","brand":"CRC Press","offers":[{"title":"Default Title","offer_id":63535987916940,"sku":"9781032919522","price":61.19,"currency_code":"USD","in_stock":true}],"url":"https:\/\/lateknightbooks.com\/products\/9781032919522","provider":"Late Knight Books and Services, LLC","version":"1.0","type":"link"}